
Top Diagnostics Stocks Compared: Dr Lal PathLabs vs Metropolis vs Thyrocare vs Krsnaa Diagnostics vs Vijaya Diagnostic on Price, Valuation, Q2 FY27 Results and Risks
Previous close: Dr Lal PathLabs Rs 1,980.20, Metropolis Rs 567.00, Thyrocare Rs 506.95, Krsnaa Diagnostics Rs 518.70, Vijaya Diagnostic Rs 1,467.40.
Updated: 18 Nov 2026 • 10:28 am
Posted by:

Quick Answer
This diagnostics stocks compared snapshot checks five names on price, valuation and Q2 FY27 results: Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic. Dr Lal PathLabs is the largest by market capitalisation at Rs 33,431 crore. Thyrocare reports the highest return on equity at 31.66%. Diagnostics chains run different models, so read each multiple next to margins and returns.
Diagnostics stocks compared here means Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic on one page, checked on previous close, market value, valuation and the latest quarterly numbers. The group covers five listed diagnostic chains, each with a different mix of home collection, hospital labs and public programmes, which is exactly why a side-by-side look helps.
All five companies have filed their September 2026 quarter, so every result below is Q2 FY27. Diagnostics stocks follow test volumes, pricing, lab capacity and health awareness, so a glance at the Nifty Pharma page and the Sensex page before you read the tables gives useful backdrop.
Click Here – Get Free Investment Predictions
Diagnostics Stocks Compared: Five Names on the List
The diagnostics stocks compared here are Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic. Dr Lal PathLabs is the largest by market capitalisation at Rs 33,431 crore. Previous closes run from Rs 506.95 for Thyrocare to Rs 1,980.20 for Dr Lal PathLabs, which is why a side-by-side look at value rather than price is more useful.
| Stock | Previous close (Rs) | Market cap (Rs crore) |
|---|---|---|
| Dr Lal PathLabs | 1,980.20 | 33,431 |
| Metropolis | 567.00 | 11,696 |
| Thyrocare | 506.95 | 7,942 |
| Krsnaa Diagnostics | 518.70 | 1,715 |
| Vijaya Diagnostic | 1,467.40 | 14,528 |
A quick look at the business behind each ticker puts the numbers in context. Dr Lal PathLabs runs diagnostic labs and collection centres, while Metropolis runs diagnostic labs. Thyrocare runs diagnostic testing labs, and Krsnaa Diagnostics runs diagnostic centres. To compare diagnostics stocks properly, line up price to earnings, return on equity and operating margin before forming a view.
Rounding out the group, Vijaya Diagnostic runs diagnostic centres. A fair diagnostics stock comparison looks at what each company actually earns from, not only at the share price. A lab chain and a public programme specialist belong in separate mental boxes whenever you compare diagnostics stocks fairly.
Diagnostics Stocks Valuation: Multiples, Returns and Payouts
Krsnaa Diagnostics trades at the lowest price to earnings ratio in this group at 17.48. Thyrocare reports the highest return on equity at 31.66%. Krsnaa Diagnostics has the lowest price to book value at 1.65. These diagnostics stocks valuation readings come from the previous close and the latest reported financials. That is the idea behind this diagnostics stocks compared table: price to earnings and return on equity sit side by side so a high or low reading stands out at once.
| Stock | Price to earnings | Price to book | ROE (%) | Dividend yield (%) | Debt to equity |
|---|---|---|---|---|---|
| Dr Lal PathLabs | 56.86 | 12.18 | 21.32 | 1.03 | 0.09 |
| Metropolis | 51.90 | 7.13 | 13.66 | 0.89 | 0.16 |
| Thyrocare | 55.44 | 14.35 | 31.66 | 2.81 | 0.10 |
| Krsnaa Diagnostics | 17.48 | 1.65 | 9.45 | 0.38 | 0.57 |
| Vijaya Diagnostic | 71.31 | 13.74 | 19.26 | 0.14 | 0.48 |
Price to earnings, return on equity, debt to equity and dividend yield give the clearest picture of valuation, returns and balance sheet room across the five names. Earnings per share and book value per share are the building blocks behind price to earnings and price to book, so a glance at both in each filing is time well spent. A simple diagnostics stock comparison like this one is only as useful as the context behind it, which is why operating margin is worth checking as well.
In this group, price to earnings runs from 17.48 for Krsnaa Diagnostics to 71.31 for Vijaya Diagnostic. Thyrocare offers the highest dividend yield at 2.81%. The sector benchmark for price to earnings is 62.49, and every stock in the table can be measured against that figure. The industry price to earnings is a handy anchor: a stock above it is priced for faster growth, and one below it is priced for steadier earnings. A well-built diagnostics stock comparison also notes that test volumes can move with seasonal illness.
Diagnostics Stocks Q2 FY27 Results: Revenue and Profit Check
All of the five diagnostics stocks compared have filed Q2 FY27 numbers. Krsnaa Diagnostics posted the fastest revenue growth at 31.9% year on year. Metropolis showed the sharpest rise in net profit at 42.7%. Read revenue first and quarterly profit second, since the two together show how much of the growth reaches shareholders. Treat the Q2 FY27 numbers in this diagnostics stocks compared review as a snapshot of one quarter, not a verdict on any diagnostics company.
| Stock | Q2 FY27 revenue (Rs crore) | Q2 FY26 revenue (Rs crore) | Q2 FY27 net profit (Rs crore) | Q2 FY26 net profit (Rs crore) |
|---|---|---|---|---|
| Dr Lal PathLabs | 908.2 | 755.4 | 193.9 | 152.2 |
| Metropolis | 505.3 | 430.1 | 75.5 | 52.9 |
| Thyrocare | 274.4 | 219.6 | ||
| Krsnaa Diagnostics | 277.1 | 210.2 | 24.6 | 23.9 |
| Vijaya Diagnostic | 260.3 | 207.8 | 59.5 | 43.3 |
Dr Lal PathLabs Results Snapshot
Dr Lal PathLabs reported Q2 FY27 revenue of Rs 908.2 crore, compared with Rs 755.4 crore a year earlier, a rise of 20.2%. Net profit rose 27.4% to Rs 193.9 crore from Rs 152.2 crore. Operating margin expanded to 36.0% from 34.1% a year ago.
Metropolis Results Snapshot
In the September 2026 quarter, Metropolis booked revenue of Rs 505.3 crore against Rs 430.1 crore in the same quarter last year, a rise of 17.5%. Net profit rose 42.7% to Rs 75.5 crore from Rs 52.9 crore. Operating margin expanded to 28.7% from 25.4% a year ago.
Thyrocare Results Snapshot
Thyrocare's Q2 FY27 top line stood at Rs 274.4 crore, versus Rs 219.6 crore in Q2 FY26, a rise of 25.0%.
Krsnaa Diagnostics Results Snapshot
Krsnaa Diagnostics reported Q2 FY27 revenue of Rs 277.1 crore, compared with Rs 210.2 crore a year earlier, a rise of 31.9%. Net profit rose 2.7% to Rs 24.6 crore from Rs 23.9 crore. Earnings per share for the quarter rose to Rs 7.54 from Rs 7.25.
Vijaya Diagnostic Results Snapshot
In the September 2026 quarter, Vijaya Diagnostic booked revenue of Rs 260.3 crore against Rs 207.8 crore in the same quarter last year, a rise of 25.3%. Net profit rose 37.4% to Rs 59.5 crore from Rs 43.3 crore. Operating margin expanded to 46.1% from 43.7% a year ago. Earnings per share for the quarter rose to Rs 5.76 from Rs 4.20.
Test volumes, pricing and lab capacity shape earnings, so each chain needs a look at its own results, so profit can look different from revenue in a single quarter. That is why a diagnostics stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, a diagnostics stocks compared review becomes a map of the sector rather than a price list. When you compare diagnostics stocks after each result season, track how operating margin changes from one quarter to the next.
Diagnostics Stocks Compared Two at a Time: Three Pairings
Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare diagnostics stocks two at a time.
Dr Lal PathLabs vs Metropolis
Dr Lal PathLabs and Metropolis are two of the largest listed diagnostic chains. Dr Lal PathLabs is about 2.9 times the size of Metropolis by market capitalisation, at Rs 33,431 crore against Rs 11,696 crore. On price to earnings, Metropolis carries the lower multiple at 51.90 against 56.86 for Dr Lal PathLabs. Dr Lal PathLabs reports the higher return on equity, at 21.32% against 13.66% for Metropolis. Two leaders with different city mixes, so read margins next to valuation.
Thyrocare vs Vijaya Diagnostic
Thyrocare runs a centralised testing model, while Vijaya runs a network of centres. On price to earnings, Thyrocare carries the lower multiple at 55.44 against 71.31 for Vijaya Diagnostic. Thyrocare reports the higher return on equity, at 31.66% against 19.26% for Vijaya Diagnostic. For dividend income, Thyrocare offers 2.81% against 0.14% at Vijaya Diagnostic. Two models with different cost structures, so compare returns first.
Krsnaa Diagnostics vs Dr Lal PathLabs
Krsnaa serves public health programmes, while Dr Lal PathLabs serves private patients. Dr Lal PathLabs reports the higher return on equity, at 21.32% against 9.45% for Krsnaa Diagnostics. For dividend income, Dr Lal PathLabs offers 1.03% against 0.38% at Krsnaa Diagnostics. In Q2 FY27, Krsnaa Diagnostics grew revenue faster, at 31.9% year on year against 20.2% for Dr Lal PathLabs. A public programme specialist and a private leader differ in customers, so read returns together.
Best Diagnostics Stocks for Each Type of Investor
People who ask for the best diagnostics stocks often have very different goals, so here is who leads on each measure today, row by row. Any diagnostics stocks compared table can mislead if you stop at one row, because each diagnostics company leads on a different measure.
| If you care most about | Start your research with | The number |
|---|---|---|
| Lowest price to earnings | Krsnaa Diagnostics | 17.48 |
| Highest return on equity | Thyrocare | 31.66% |
| Highest dividend yield | Thyrocare | 2.81% |
| Lowest price to book value | Krsnaa Diagnostics | 1.65 |
| Largest by market capitalisation | Dr Lal PathLabs | Rs 33,431 crore |
| Fastest Q2 FY27 revenue growth | Krsnaa Diagnostics | 31.9% |
| Sharpest Q2 FY27 net profit rise | Metropolis | 42.7% |
No single name tops every row, which is exactly why a diagnostics stock comparison helps. Margins, returns and valuation point to different companies, so decide what matters most to you before you rank the numbers.
What Is Driving Diagnostics Stocks Right Now?
Diagnostic chains earn from tests that people book regularly, so readers study them as a steady healthcare theme. Knowing what moves test volumes and pricing helps you compare diagnostics stocks with the right questions in mind.
Test volumes, pricing and lab capacity decide earnings, so growth in patient visits matters. A good diagnostics stocks compared routine therefore tracks test volumes, pricing and quarterly results.
Risks to Weigh When You Compare Diagnostics Stocks
Diagnostics stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Every diagnostics stock comparison has blind spots, and for this group the biggest is test volumes and pricing.
Because test volumes, pricing and quarterly results drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this diagnostics stocks compared guide a balanced starting point.
How to Compare Diagnostics Stocks and Build a Shortlist
Start by deciding which diagnostic model you want exposure to, because each reads the market differently. Readers who follow test volumes, pricing and quarterly results find the group easier to track. Done step by step, this diagnostics stocks compared routine becomes repeatable rather than a one-off exercise.
Then check valuation and returns, because the five names rarely trade on the same multiple. A centralised testing lab next to a centre network shows how the business behind each price changes the numbers. Keep the shortlist of best diagnostics stocks short enough that you can actually follow each company's quarterly results.
The Univest stock screener lets you filter diagnostics stocks by market capitalisation, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this diagnostics stocks compared page after the next set of results to see which numbers have moved.
Check the Univest Screener for live diagnostics stock data
Download the Univest iOS App or Univest Android App to track these diagnostics stocks live.
Conclusion: Diagnostics Stocks Compared at a Glance
This diagnostics stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Dr Lal PathLabs leads on size and Thyrocare leads on return on equity, while the others bring their own strengths. Treat the diagnostics stocks Q2 FY27 results and diagnostics stocks valuation tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare diagnostics stocks again next quarter, the same checklist of price to earnings, return on equity and operating margin will work.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Diagnostics Stocks Compared
Which are the top diagnostics stocks compared in this article?
Ans. The diagnostics stocks compared in this article are Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, giving you a quick, even-handed view of the group ahead of any detailed filing review.
Which diagnostics stock has the highest market capitalisation?
Ans. Among the five names, Dr Lal PathLabs has the highest market capitalisation at Rs 33,431 crore. Vijaya Diagnostic follows at Rs 14,528 crore. The figure reflects what the market is paying for the whole company today, and it will change as prices move, so refresh it before you decide.
Which of these diagnostics stocks has the lowest price to earnings ratio?
Ans. On diagnostics stocks valuation, Krsnaa Diagnostics has the lowest price to earnings ratio among these diagnostics stocks at 17.48, based on the latest reported earnings. Vijaya Diagnostic sits at the other end at 71.31. The lowest ratio is not a verdict on the stock, since earnings growth and quality decide whether a multiple is fair.
Which diagnostics stock has the highest return on equity?
Ans. Thyrocare reports the highest return on equity in this group at 31.66%. A higher return on equity points to a company that turns shareholder funds into profit efficiently. Check the trend over time and the debt level before leaning on a single reading.
How did diagnostics stocks perform in Q2 FY27 results?
Ans. All of the five names have filed Q2 FY27 numbers in our data. Krsnaa Diagnostics recorded the fastest revenue growth at 31.9% year on year. Metropolis showed the sharpest net profit rise at 42.7%. For diagnostics stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.
What are the main risks when you compare diagnostics stocks?
Ans. Diagnostics stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Keep an eye on test volumes, pricing and quarterly results.
Which metrics matter most when you compare Diagnostics stocks?
Ans. Revenue growth, operating margin, return on equity and price to earnings matter most here. Compare each multiple with the company's own test volume trend. Read each filing for volume and pricing commentary.
Which is the best diagnostics stock to buy among these five?
Ans. The best Diagnostics stock depends on which diagnostic model you want exposure to, because the five names differ on all of these. On the numbers in this article, Dr Lal PathLabs has the largest market capitalisation; Krsnaa Diagnostics has the lowest price to earnings; Thyrocare has the highest return on equity as well as the highest dividend yield. The leaders change from row to row, so no stock stands out on everything, and this article is not advice. Shortlist from the tables, verify with the latest filings, and consult a SEBI-registered advisor, since time horizon and risk appetite matter most.
Recent Articles

Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
Top Budget 2027 Infrastructure Stocks Compared: Kalpataru Projects vs KEC International vs HG Infra vs PNC Infratech vs NBCC on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





